A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 24, 2025

Primary Completion Date

January 8, 2029

Study Completion Date

January 8, 2029

Conditions
Pulmonary Hypertension
Interventions
DRUG

PF-07868489

Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY